Modality
siRNA
MOA
EZH2i
Target
FGFR
Pathway
T-cell
PsA
Development Pipeline
Preclinical
~Sep 2009
→ ~Dec 2010
Phase 1
~Mar 2011
→ ~Jun 2012
Phase 2
~Sep 2012
→ ~Dec 2013
Phase 3
~Mar 2014
→ ~Jun 2015
NDA/BLA
~Sep 2015
→ ~Dec 2016
Approved
Mar 2017
→ Dec 2031
ApprovedCurrent
NCT08878966
1,944 pts·PsA
2019-11→2031-12·Terminated
NCT03423876
1,829 pts·PsA
2017-03→2026-11·Not yet recruiting
NCT03706285
393 pts·PsA
2021-01→2031-04·Not yet recruiting
+1 more trial
6,110 total pts1 indication
CompletedCurrentUpcoming
Catalysts (4)
2026-11-057mo awayPh3 Readout· PsA
2030-08-264.4y awayPh3 Readout· PsA
2031-04-285.1y awayPh3 Readout· PsA
2031-12-115.7y awayPh3 Readout· PsA
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Approved
Not yet…
Approved
Termina…
Approved
Not yet…
Approved
Not yet…
Catalysts
Ph3 Readout
2026-11-05 · 7mo away
PsA
Ph3 Readout
2030-08-26 · 4.4y away
PsA
Ph3 Readout
2031-04-28 · 5.1y away
PsA
Ph3 Readout
2031-12-11 · 5.7y away
PsA
TerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08878966 | Approved | PsA | Terminated | 1944 | Safety |
| NCT03423876 | Approved | PsA | Not yet recr... | 1829 | CR |
| NCT03706285 | Approved | PsA | Not yet recr... | 393 | MRD |
| NCT03778520 | Approved | PsA | Not yet recr... | 1944 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 |